✦ LIBER ✦

P.056 Virological and clinical correlates of hepatitis B virus (HBV) DNA levels in patients with HBe-negative, genotype D chronic hepatitis B

✍ Scribed by S. Chevaliez; G. Germanidis; F. Roudot-Thoraval; M. Bouvier-Alias; F. Guerre; A. Miladi; I. Makri; S. Manolakopoulos; D. Demitrios; E. Pagkalos; A. Avgerinos; G. Dalekos; J. Pawlotsky

Book ID: 117770279
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 144 KB
Volume: 36
Category: Article
ISSN: 1386-6532
DOI: 10.1016/s1386-6532(06)80239-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.137 Correlation between hepatitis B vi

P.137 Correlation between hepatitis B virus genotype and HBV DNA level in chronic hepatitis B patients

✍ M.A. Mahtab; M. Khan; S. Rahman 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 278 KB

Viral genotype and hepatitis B virus DNA

Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection

✍ Henry Lik-Yuen Chan; Steven Woon-Choi Tsang; Chook-Tiew Liew; Chi-Hang Tse; May- 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 95 KB

Four years of treatment with lamivudine:

Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B

✍ S. Gaia; A. Marzano; A. Smedile; V. Barbon; M. L. Abate; A. Olivero; M. Lagget; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

P.009 Epidemiological characteristics of

P.009 Epidemiological characteristics of HBV inactive chronic carriers and comparison with hbe antigen negative chronic hepatitis B patients

✍ J. Zarski; P. Marcellin; V. Leroy 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 263 KB

489 What does the hepatitis B virus DNA

489 What does the hepatitis B virus DNA level tell us in HBeAg-negative patients infected with HBV genotype D?

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60